Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for overweight and obesity in people with schizophrenia: pilot study
2017-004064-35Phase 4Unknown
- Sponsor
- Southern Health NHS Foundation Trust
- Start
- Feb 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Overweight, obesity, schizophrenia and 2 more comparing Liraglutide (Saxenda) with Placebo (2 arms). Primary endpoint: Feasibility and acceptability of delivering a full-scale liraglutide trial in people with schizophrenia. Status: unknown.
02
Drugs
03
Conditions
Overweightobesityschizophreniaschizoaffective disorderpsychosis
Beyond the preview
Go deeper on 2017-004064-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004064-35.